Is it really that obvious? Understanding and combating obviousness rejections under 35 U.S.C. 103 before the USPTO

Audience

All

Event information

Is it really that obvious? Understanding and combating obviousness rejections under 35 U.S.C. 103 before the USPTO
Start date Thursday, February 18, 2021 02:00 PM
End date Thursday, February 18, 2021 03:00 PM
CPD Points 1.0
Price Non Member £73.20 (Includes £12.20 VAT)
Member £0.00 (Includes £0.00 VAT)

Synopsis

Obviousness rejections are ubiquitous when dealing with the USPTO. Although they are commonplace in examination, it can be difficult to clearly identify the Examiner’s concerns reflected in the rejection and to plot a path to patentable claims. Our discussion will focus on these rejections with suggestions for overcoming them and working with your Examiner to find a way forward.

Speaker Info

Hulse_Loren Circle.png

Loren Hulse, Partner at Holland & Hart, delivers sophisticated counsel in the creation, management, and protection of domestic and foreign patent and trademark portfolios to companies disrupting the life sciences, chemical, pharmaceutical, biotech, manufacturing, and medical device industries.

From his experience working as former in-house intellectual property counsel for NPS Pharmaceuticals and as patent counsel for Ceramatec, Inc., Loren understands the business imperative to create robust protection strategies while managing patent and trademark portfolios that align with corporate priorities.

As a practitioner, Loren has developed, managed, and protected both large and small domestic and foreign patent and trademark portfolios. His wide-ranging biotech and pharmaceutical experience includes advising clients how to protect small molecule and peptide drugs, methods of treatment, genetic constructs and therapies, nucleotide analogs, and RNA-related drug technologies. He has also counseled clients developing medical devices such as optically-guided feeding tubes, injectors, diagnostic kits, catheters, and cardiac assist devices. In the chemical arena, Loren’s experience includes assisting clients to protect solid oxide fuel cell technologies, ionically-conductive membrane applications, and syngas production techniques.

Before joining Holland & Hart, Loren was a partner at Stoel Rives, where he served as the co-leader of the firm’s Life Sciences industry group.